论文部分内容阅读
背景大量研究证实β1受体阻滞剂治疗急性冠状动脉综合征(ACS)有益,但作用机制尚不明确。目的探讨β1肾上腺素受体阻滞剂对健康人及ACS患者外周血单个核细胞一些炎症因子表达的影响。方法应用不同剂量的β1肾上腺素能受体阻滞剂艾司洛尔体外分别和健康人及ACS患者外周血孵化后,采用流式细胞术测定CD14+单个核细胞Toll样受体4(TLR4)的表达,RT-PCR法测定单个核细胞TLR4mRNA的表达,ELISA法测定血清中白细胞介素6(IL-6)、白细胞介素18(IL-18)水平。结果艾司洛尔下调了健康人及ACS患者外周血单个核细胞TLR4蛋白及mRNA、IL-6、IL-18的表达,并呈现一定的剂量依赖性。结论β1受体阻滞剂应用于健康人及ACS患者可抑制TLR4及其下游炎症因子的表达。
Background A large number of studies have shown that β1-blocker treatment of acute coronary syndrome (ACS) beneficial, but the mechanism is not yet clear. Objective To investigate the effect of β1 adrenergic receptor blocker on the expression of some inflammatory cytokines in peripheral blood mononuclear cells in healthy volunteers and ACS patients. Methods After different doses of estrogen β1 adrenergic receptor antagonist esmolol were incubated in peripheral blood of healthy people and ACS patients respectively, the levels of Toll-like receptor 4 (TLR4) in CD14 + mononuclear cells were measured by flow cytometry The expression of TLR4 mRNA in mononuclear cells was detected by RT-PCR. The levels of IL-6 and IL-18 in serum were measured by ELISA. Results Esmolol down-regulated the expression of TLR4 protein, mRNA, IL-6 and IL-18 in peripheral blood mononuclear cells of healthy people and ACS patients in a dose-dependent manner. Conclusion β1 blockers can inhibit the expression of TLR4 and its downstream inflammatory cytokines in healthy people and patients with ACS.